Sgd Pharma India Profile
Key Indicators
- Authorised Capital ₹ 212.00 Cr
as on 15-05-2024
- Paid Up Capital ₹ 207.11 Cr
as on 15-05-2024
- Company Age 14 Year, 10 Months
- Last Filing with ROC 31 Dec 2022
- Open Charges ₹ 63.41 Cr
as on 15-05-2024
- Satisfied Charges ₹ 109.88 Cr
as on 15-05-2024
About Sgd Pharma India
The Corporate was formerly known as Cogent Glass Limited. The Company is engaged in the Packaging Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 December 2022. It's a company limited by shares with an authorized capital of Rs 212.00 Cr and a paid-up capital of Rs 207.11 Cr.
The company currently has active open charges totaling ₹63.41 Cr. The company has closed loans amounting to ₹109.88 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Sgd Pharma India Private Limited India are Akshay Singh as Ceo, Mukul Kumar as Cfo, and Soma Bhaumik as Company Secretary. Sardar Akshay and Olivier Francois serve as directors at the Company.
- CIN/LLPIN
U26100TG2009PTC065810
- Company No.
065810
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Nov 2009
- Date of AGM
30 Jun 2023
- Date of Balance Sheet
31 Dec 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Mahabub Nagar, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sgd Pharma India?
Executive Team (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sardar Akshay  | Managing Director | 27-Jul-2017 | Current |
| Akshay Singh | CEO | 02-Dec-2016 | Current |
| Mukul Kumar | CFO | 28-May-2020 | Current |
| Soma Bhaumik | Company Secretary | 24-Feb-2021 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Olivier Francois | Director | 06-Oct-2022 | Current |
Financial Performance and Corporate Structure Insights of Sgd Pharma India.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Sgd Pharma India?
Unlock access to Sgd Pharma India's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
54 years 3 months Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 09 Nov 2012 | ₹63.41 Cr | Open |
Others Creation Date: 24 Feb 2020 | ₹0.60 M | Satisfied |
Icici Bank Limited Creation Date: 18 Feb 2012 | ₹30.00 Cr | Satisfied |
How Many Employees Work at Sgd Pharma India?
Unlock and access historical data on people associated with Sgd Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sgd Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sgd Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
